LID.L Regulatory News (LID)

25 Oct 2005 07:01

LiDCO Group Plc25 October 2005 For immediate release 25 October 2005 LIDCO GROUP PLC ("LiDCO" or "the Company") CLINICAL ADVISORY BOARD APPOINTMENT 25 October 2005: LiDCO Group plc (AIM: LID), the cardiovascular monitoringcompany, is pleased to announce that Professor Michael R. Pinsky, has joined itsClinical Advisory Board. Professor Pinsky is Professor of Critical Care Medicine, Bioengineering andAnesthesiology at the University of Pittsburgh School of Medicine, USA and is amember of the editorial board of the American Journal of Respiratory andCritical Care Medicine, Intensive Care Medicine, Journal of Critical Care andCritical Care Forum. He is editor-in-chief of the eMedicine textbook CriticalCare Medicine. He has a wide range of research interests - among them being thestudy of heart-lung interactions, hemodynamic monitoring, cardiovascularphysiology, sepsis and outcomes research. He is a world leading authority on theapplication of both existing invasive, and the more recent minimally invasive,monitoring technologies to optimise cardiovascular physiology and therebyimprove outcomes in critically ill patients. Dr Terry O'Brien, LiDCO's Chief Executive, commented: "I am delighted to welcomeProf Michael Pinsky to our Clinical Advisory Board. Michael is internationallyrenowned for his work on functional hemodynamic monitoring and its applicationto the care of critically ill patients. His combination of clinical and researchexperiences will make a significant contribution to the evolution of LiDCO'sfuture product development strategy." Prof Michael Pinsky commented: "I am very pleased to be associated with LiDCOand their innovative technology. I believe that their ability to apply cuttingedge technologies coupled with our evolving understanding of the interactionbetween disease and treatment will result in novel and effective treatmentprotocols. The adoption of technology such as LiDCO's will be a key factor inimproving patient outcomes in a cost-effective fashion." For further information please contact: LiDCO Group PlcTerry O'Brien (CEO) terry@lidco.com 020 7749 1500Hugh McGarel-Groves (FD) hugh.mcgarel-groves@lidco.com Buchanan Communications Tim Anderson, Mary-Jane Johnson, James Strong 020 7466 5000 Panmure GordonAubrey Powell, Katherine Roe 020 7459 3600 Notes for Editors About LiDCO Plc LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier ofminimally invasive, computer-based hemodynamic monitoring equipment anddisposables used primarily for the management of critical care andcardiovascular risk hospital patients. Use of LiDCO's technology has been shownto significantly reduce the complications (particularly infections) and costsassociated with major surgery. The technology was invented in the Department ofApplied Physiology based at St Thomas' Hospital, London where the Companymaintains a research base. The Company's manufacturing facility is in Hoxton, London and its currentproducts are: • LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume; • LiDCO disposables: used in conjunction with the LiDCOplus Monitor accurately determine cardiac output in a minimally-invasive manner. Distribution Network: The Company has now achieved registration of its products in 13 markets inEurope, the USA, Brazil and Japan. It sells direct to the NHS in the UK, andthrough a worldwide network of specialty critical care distributors. Background to the recently published clinical trial: Better than standard care -(EGDT) improves outcome in high risk surgery patients: The results of a major trial at St George's Hospital, London using LiDCO'sminimally invasive monitoring technology were presented during the 25thInternational Symposium on Intensive Care and Emergency Medicine in Brussels(21st to 25th March) and the full paper will be published on November 8th inCritical Care Medicine. The results have revealed the following: a) Savings in the cost of treating patients amounting to an average of £4,000 per patient. Extrapolated nationally, this would equate to a saving of £500 million per annum for the NHS b) The monetary saving (£248,000) - resulted from 640 hospital days saved for 62 patients, an average of more than 10 bed days per patient c) The savings in cost and hospital days were associated with a significant reduction in medical complications (particularly infections - which were halved) through the use of LiDCO's minimally invasive technology to improve tissue oxygen levels following surgery. This information is provided by RNS The company news service from the London Stock Exchange